Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 131

Sort by

Sort Order Select

Journal Articles

Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael A. Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin T. Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood blood.2024026212.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

Plasma cells’ fate: it is a complex “orchestra”

Paola Neri

Blood (2024) 144 (5): 466–467.

https://doi.org/10.1182/blood.2024025016

Published: 2024

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 function over forms in multiple myeloma

Paola Neri, Lawrence H. Boise

Blood (2024) 143 (13): 1202–1204.

https://doi.org/10.1182/blood.2023023487

Published: 2024

Journal Articles

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Noémie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence H. Boise, Nizar Bahlis, Paola Neri

Blood (2024) 143 (1): 42–56.

https://doi.org/10.1182/blood.2023020276

Published: 2024

Includes: Supplemental data

Journal Articles

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

Mansour Poorebrahim, Holly Lee, Sacha Benaoudia, Ranjan Maity, Sungwoo Ahn, Noémie Leblay, Elie Barakat, Remi Tilmont, Douglas Mahoney, Lawrence H. Boise, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 454.

https://doi.org/10.1182/blood-2023-189747

Published: 2023

Journal Articles

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Holly Lee, Michael Durante, Sungwoo Ahn, Noemie Leblay, Mansour Poorebrahim, Ranjan Maity, Rémi Tilmont, Elie Barakat, David Jung, Bachisio Ziccheddu, Alexis Brake, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2023-188080

Published: 2023

Journal Articles

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

Holly Lee, Sungwoo Ahn, Ranjan Maity, Noémie Leblay, Michael Durante, Bachisio Ziccheddu, Alexis Brake, Remi Tilmont, Elie Barakat, Mansour Poorebrahim, Ola Landgren, Benjamin Diamond, Francesco Maura, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2023-190517

Published: 2023

Journal Articles

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Noemie Leblay, Sungwoo Ahn, Sheri Skerget, Rémi Tilmont, Holly Lee, Mansour Poorebrahim, Daniel Penaherrera, Elie Barakat, David Jung, Nizar J Bahlis, Jonathan Keats, Paola Neri

Blood (2023) 142 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2023-189567

Published: 2023

Journal Articles

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 604–605.

https://doi.org/10.1182/blood-2022-169721

Published: 2022

Journal Articles

CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Remi Tilmont, Ranjan Maity, Noemie Leblay, Holly Lee, Elie Barakat, Paola Neri, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 9964–9965.

https://doi.org/10.1182/blood-2022-169550

Published: 2022

Journal Articles

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Son Tran, Ritul Sharma, Chunfen Zhang, Ranjan Maity, Amy J. Johnson, Melanie M. Frigault, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, Nizar J. Bahlis, Paola Neri, Aru Narendran

Blood (2022) 140 (Supplement 1): 10685–10686.

https://doi.org/10.1182/blood-2022-169917

Published: 2022

Journal Articles

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

Holly Lee, Paola Neri, Sungwoo Ahn, Ranjan Maity, Noemie Leblay, Bachisio Ziccheddu, Monika Chojnacka, Rémi Tilmont, Elie Barakat, Ola Landgren, Francesco Maura, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 252–253.

https://doi.org/10.1182/blood-2022-167602

Published: 2022

Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12997.

https://doi.org/10.1182/blood-2022-169920

Published: 2022

Journal Articles

Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma

Paola Neri, Sungwoo Ahn, Holly Lee, Noemie Leblay, Mirco Friedrich, Ranjan Maity, Rémi Tilmont, Elie Barakat, Marc S Raab, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 2093–2094.

https://doi.org/10.1182/blood-2022-164717

Published: 2022

Journal Articles

Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers

Mirco Friedrich, Paola Neri, Noemie Leblay, Niklas Kehl, Julius Michel, Holly Lee, Elie Barakat, Sungwoo Ahn, Hartmut Goldschmidt, Michael Platten, Niels Weinhold, Marc-Steffen Raab, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 731.

https://doi.org/10.1182/blood-2021-152149

Published: 2021

Journal Articles

Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency

Noemie Leblay, Sungwoo Ahn, Ranjan Maity, Holly Lee, Elie Barakat, Nizar J. Bahlis, Paola Neri

Blood (2021) 138 (Supplement 1): 725.

https://doi.org/10.1182/blood-2021-152993

Published: 2021

Journal Articles

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

Seth Welsh, Daniel Riggs, Erin Meermeier, Chang-Xin Shi, Victoria Garbitt, Meaghen E Sharik, Megan Du, Kennedi Todd, Zachary Hammond, Sochilt Brown, Caleb K Stein, Paola Neri, Nizar J. Bahlis, Benjamin G Barwick, Larry H. Boise, W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel

Blood (2021) 138 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2021-147551

Published: 2021

Journal Articles

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

Ranjan Maity, Sacha Benaoudia, Franz Zemp, Holly Lee, Elie Barakat, Noemie Leblay, Sungwoo Ahn, Douglas Mahoney, Paola Neri, Nizar J. Bahlis

Blood (2021) 138 (Supplement 1): 327.

https://doi.org/10.1182/blood-2021-153871

Published: 2021

Journal Articles

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, María Ortiz Estévez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta

Blood (2021) 137 (2): 232–237.

https://doi.org/10.1182/blood.2020007081

Published: 2021

Includes: Supplemental data

NARROW

Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Plasma cells’ fate: it is a complex “orchestra”

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

TP53 function over forms in multiple myeloma

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma

Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance

A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma

Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers

Integrated Epigenetic and Transcriptional Single Cell Analysis of t(11;14) Myeloma and Its BCL2 Dependency

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only